NIH says type of hormone therapy hurts instead of helping women's hearts and causes breast cancer
Tuesday, July 9th 2002, 12:00 am
By: News On 6
WASHINGTON (AP) _ Government scientists abruptly ended the nation's biggest study of a type of hormone replacement therapy, saying long-term use of estrogen and progestin significantly increased the women's risk of breast cancer, strokes and heart attacks.
Six million American women use this hormone combination, either for short-term relief of hot flashes and other menopausal symptoms or because of doctors' longstanding assumptions that long-term use would prevent heart disease and brittle bones and generally keep women healthier longer.
Two of those assumptions are wrong, the National Institutes of Health announced Tuesday. In fact, yearslong use of estrogen and progestin increased otherwise healthy women's risk of a stroke by 41 percent, a heart attack by 29 percent and breast cancer by 24 percent.
On the good side, it cut by a third the risk of colon cancer and hip fractures _ but there are other ways to fend off those illnesses, doctors noted.
Concluding the hormones' risks outweighed those benefits, the NIH stopped the 16,600-woman study three years early _ and is advising other women who use the estrogen-progestin combination to ask their doctors if they, too, should quit.
If you're using it for heart disease, ``forget about it,'' said Dr. Jacques Rossouw, acting director of the NIH's Women's Health Initiative, which sponsored the study. ``For osteoporosis, in some women there may be a place. For promoting overall health, our data suggests it's not a good idea.''
Other researchers were more negative.
``We recommend that clinicians stop prescribing this combination for long-term use,'' wrote Dr. Suzanne Fletcher of Harvard Medical School in an editorial accompanying the study results posted on the Web site of the Journal of the American Medical Association. ``Risks from the drug add up over time.''
The study's leaders stressed that women shouldn't panic because personal risk is pretty small.
In one year, for every 10,000 women who take the estrogen-progestin combination there will be eight more breast cancers, eight more strokes and seven more heart attacks _ and six fewer colon cancers and five fewer hip fractures _ compared with 10,000 women who didn't take the pills.
However, because millions take the hormones, those numbers can add up to thousands of illnesses, Rossouw noted.
To use estrogen or not has long been a vexing question for women entering menopause. While the study seems definitive, it doesn't settle all the questions:
_What about women who use estrogen alone? The NIH is letting a second, smaller study of those women continue for now, saying so far the balance of risks and benefits remains uncertain. Only women who have had hysterectomies can use estrogen alone, because it causes uterine cancer unless balanced by progestin.
_How do the risks stack up for short-term use? In the latest study, the cardiovascular risk actually jumped within the first year of use while the cancer risk didn't appear until around year four.
``The message still goes back to treat your individual needs,'' said study co-author Jennifer Hays of the Baylor College of Medicine. ``If you can't sleep for three weeks (because of night sweats) and short-term therapy at a low dose helps you with that, quality of life is an important thing.''
_This study used Prempro, the most popular estrogen-progestin combination. But what about lower-dose pills or even skin patches?
Without testing each, ``you can get wrong answers,'' cautioned study co-author Dr. Norman Lasser of the University of Medicine and Dentistry of New Jersey, who wants drug companies to do such testing. ``It's going to be a while 'til we know what's safe.''
Wyeth Pharmaceuticals, which makes Prempro and other estrogen supplements, said the main reason women start hormone therapy is to relieve hot flashes, night sweats or vaginal problems.
``It is important to recognize the critical role'' the hormones play for those women, said Wyeth vice president Dr. Victoria Kusiak.